Tags

Type your tag names separated by a space and hit enter

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Bone Marrow Transplant. 2005 Mar; 35(6):601-8.BM

Abstract

In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI. After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD. A total of 15 patients achieved a disease response. Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI. At the time of the last follow-up, 19 (63%) patients died and 11 (37%) remain alive. The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively. A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation.

Authors+Show Affiliations

Service d'Hématologie Clinique, Hôpital Edouard Herriot, Lyon cedex, France. annesophie.michallet@voila.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15756285

Citation

Michallet, A S., et al. "Outcome and Long-term Follow-up of Alloreactive Donor Lymphocyte Infusions Given for Relapse After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantations (HSCT)." Bone Marrow Transplantation, vol. 35, no. 6, 2005, pp. 601-8.
Michallet AS, Nicolini F, Fürst S, et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 2005;35(6):601-8.
Michallet, A. S., Nicolini, F., Fürst, S., Le, Q. H., Dubois, V., Hayette, S., Bourgeot, J. P., Tremisi, J. P., Thomas, X., Gebuhrer, L., & Michallet, M. (2005). Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplantation, 35(6), 601-8.
Michallet AS, et al. Outcome and Long-term Follow-up of Alloreactive Donor Lymphocyte Infusions Given for Relapse After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantations (HSCT). Bone Marrow Transplant. 2005;35(6):601-8. PubMed PMID: 15756285.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). AU - Michallet,A S, AU - Nicolini,F, AU - Fürst,S, AU - Le,Q H, AU - Dubois,V, AU - Hayette,S, AU - Bourgeot,J P, AU - Tremisi,J P, AU - Thomas,X, AU - Gebuhrer,L, AU - Michallet,M, PY - 2005/3/10/pubmed PY - 2005/7/8/medline PY - 2005/3/10/entrez SP - 601 EP - 8 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 35 IS - 6 N2 - In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI. After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD. A total of 15 patients achieved a disease response. Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI. At the time of the last follow-up, 19 (63%) patients died and 11 (37%) remain alive. The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively. A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/15756285/Outcome_and_long_term_follow_up_of_alloreactive_donor_lymphocyte_infusions_given_for_relapse_after_myeloablative_allogeneic_hematopoietic_stem_cell_transplantations__HSCT__ L2 - https://doi.org/10.1038/sj.bmt.1704807 DB - PRIME DP - Unbound Medicine ER -